SAN FRANCISCO, July 22, 2015 (GLOBE NEWSWIRE) -- BioQuiddity Incorporated, a late stage specialty pharmaceutical company focused on the development and commercialization of large volume ready-to-use infusible pharmaceuticals, announced today that it has appointed Daniel Tassé to its board of directors, effective immediately.
Josh Kriesel, President and Chief Executive Officer, commented, "We are thrilled to have Daniel join our Board. His extensive executive management experience in the health care arena will add enormous value to the company as we pursue the commercialization of our lead ropivacaine and propofol infusion pharmaceuticals and build out our late stage pipeline. Daniel's commercial track record will be invaluable as the company continues to execute its business plan."
"BioQuiddity's infusion pharmaceuticals are poised to address critical unmet needs, such as medication error, efficiency, value to providers, and patient quality of life. I look forward to helping advance the Company's vision of setting a new standard of care in the presentation and administration of infusible pharmaceuticals," remarked Mr. Tassé.
Mr. Tassé was formerly the President and Chief Executive Officer and Chairman of the board of directors of Ikaria, which was sold in April 2015 to Mallinckrodt for $2.3 billion. Prior to Ikaria, Mr. Tassé was the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc., and Vice President and Regional Director for Australasia at GlaxoSmithKline. He currently serves on the board of several publicly traded companies, including Bellerophon Therapeutics and Indivior PLC, a company traded on the London Stock Exchange. Mr. Tassé was a member of the Healthcare Leadership Council (2010 to June 2015) and of the Health Section Governing Board of the Biotechnology Industry Organization (2011 to June 2015), where he participated on the bioethics, regulatory environment and reimbursement committees. Mr. Tassé received a B.S. in biochemistry from the University of Montreal.
BioQuiddity Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform addresses some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQuiddity's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQuiddity's existing commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, and West Pharmaceutical Services.
CONTACT: Company Contact Information: Josh Kriesel President and CEO 415-336-6496 Ron Pauli Chief Financial Officer 415-889-7707 Investors/Media: Stephanie Carrington Integrated Corporate Relations, Inc (ICR) email@example.com 646-277-1282Source: BioQuiddity